Judge orders J&J to cover fees in Risperdal suit; Global M&A hits Indian contract manufacturers;

@FiercePharma: M&A 'boom' to continue with spate of U.S.-foreign buyouts. News | Follow @FiercePharma

> A Louisiana judge ordered Johnson & Johnson to cover $73 million worth of the state's legal costs in a $257 million verdict over the marketing of its Risperdal antipsychotic drug. Story

> Mergers & acquisitions in the global pharmaceutical industry that have led to reduction in outsourced work have hit Indian contract drug manufacturing and research services. Report

> NICE's chief executive Sir Andrew Dillon says he believes plans to introduce value-based pricing of medicines will not have a negative effect on the pharma industry. News

> Novartis won backing from the European Medicines Agency for its blood pressure drug Rasilamlo, marketed in the U.S. as Tekamlo. Item

> AstraZeneca's MedImmune subsidiary is to receive $92.5 million as part of a legal settlement involving its respiratory drug Synagis. Article

> Genzyme has agreed to drop its infringement suit with Medicis regarding the cosmetic injection product Restylane in exchange for a lump sum payment from Q-Med. Story

> Virginia will continue to be the only state with an almost-mandatory requirement that girls receive a vaccine to prevent cervical cancer, a state Senate committee decided. Item

> Dendreon has filed for building permits to take space in the Russell Investments Center in downtown Seattle and is reportedly close to signing leases for lab space in South Lake Union formerly occupied by ZymoGenetics. Report

Biotech News

@FierceBiotech: Inspire slashes 65 jobs, drops failed CF drug in restructuring. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see Cambridge/Boston going and blowing as other biotech regions shrink. Cancer is a particularly hot field. Follow @JohnCFierce 

> Focus at Genzyme now shifts to job security, partnerships. News

> Exelixis opens books on promising set of "cabo" cancer data. Article

> Bayer will hold its 2012 R&D budget at $4B. News 

> Fast Company highlights 10 top innovators in biotech. Article 

> Okarma takes $5M severance deal on his way out of Geron. Story 

And Finally... Mouse researchers conducting stress hormone experiments have stumbled onto a surprising new discovery--a potential treatment for hair loss. News

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.